Coordinators of the scientific report: G. Simone - A. Vidiri

This Line bases its assumptions on the use of innovative diagnostic approaches and technologies, functional imaging and/or molecular methodologies, and the effectiveness of minimally invasive and multimodal/integrated treatments that now represent the standard therapeutic approach for many types of cancer. Technological advances in bio-molecular research, imaging, minimally invasive surgery, radiotherapy and new oncological target therapies require increasing efforts towards a more accurate diagnosis and more personalized therapy. The integration of synergistic and complementary skills (molecular biology and pathological anatomy, endoscopy, surgery, radiotherapy, radiology, nuclear medicine and medical physics) is the pivot for the improvement of diagnosis and treatment both for the most common tumors (e.g. colorectal, lung, breast and prostate) and for rarer tumors (e.g. melanoma, head-neck, thyroid, pancreas, soft tissue sarcomas, hepatocarcinomas). IRE translational research teams will allow the integration of clinical information with the parameters extracted from biomedical images and functional analysis at cellular and molecular level, allowing a more appropriate customization of treatment. The study of new preclinical models (primary tumor cultures, 3D cell growth models, xenopatients, innovative animal models of tumor disease, development of models for drug repurposing), preclinical and clinical validation of innovative diagnostic tools (genomic tests), proteomics, metabolomics in tissues and/or biological fluids, development of new models for target identification through genetic manipulation with CRISPS/Cas9 technology), development of new combined therapeutic approaches (surgery, radiation, nanoparticles, ultrasound, heat, etc.). ) taking into account clinically available advanced technologies (robotic and minimally invasive surgery, focal therapies, radiotherapy, radiosurgery and SBRT, medical-nuclear therapy, radiomics) will allow to identify new prognostic/predictive biomarkers and to test innovative therapeutic approaches for personalised therapy, a goal for translational research.